SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...

Citi analyst Joanne Wuensch keeps a Buy rating on Edwards Lifesciences (EW) with an $81 price target after the company presented its EARLY TAVR clinical data, saying it came in better than expected ...

Edwards Lifesciences secures FDA clearance for its ECLIPTIS Left Atrial Appendage Exclusion System, entering a competitive ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...

Edwards Lifesciences (EW) announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis and ...

Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

Edwards Lifesciences Corp. EW is scheduled to report third-quarter 2025 results on Oct. 30, after market close. In the last reported quarter, the company’s adjusted earnings per share of 67 cents beat ...

Edwards Lifesciences Corp (NYSE:EW) reported Wednesday second-quarter adjusted EPS of 70 cents, beating the consensus of 69 cents. The sales increased 7% (+8% on constant currency) to $1.632 billion, ...

Edwards delivered $1.55 billion in Q3 2025 revenue, beating estimates by $50 million. The company’s TAVR franchise continues dominating a market Edwards helped create. CEO Bernard Zovighian raised ...